Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
J Infect Dis
    March 2024
  1. WHITTAKER R, Midtbo JE, Klovstad H
    Monitoring progress towards the elimination of hepatitis C as a public health threat in Norway: a modelling study among people who inject drugs and immigrants.
    J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093.
    >> Share

  2. KAMILI S, Wester C
    Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in the United States.
    J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093.
    >> Share

  3. HESTERMAN MC, Fallon BS, Lynch KM, Weller ML, et al
    Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000-2021.
    J Infect Dis. 2024 Mar 8:jiae023. doi: 10.1093.
    >> Share

  4. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
    Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
    J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
    >> Share

    February 2024
  5. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
    The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
    J Infect Dis. 2024 Feb 28:jiae087. doi: 10.1093.
    >> Share

  6. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
    Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
    J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
    >> Share

  7. MUSONDA T, Wallace MS, Patel H, Martin OP, et al
    New window into hepatitis B in Africa: Liver sampling combined with single cell omics enables deep and longitudinal assessment of intrahepatic immunity in Zambia.
    J Infect Dis. 2024 Feb 9:jiae054. doi: 10.1093.
    >> Share

    January 2024
  8. RINGLANDER J, Stromberg LG, Stenback JB, Andersson ME, et al
    Enrichment reveals extensive integration of hepatitis B virus DNA in hepatitis delta-infected patients.
    J Infect Dis. 2024 Jan 25:jiae045. doi: 10.1093.
    >> Share

    October 2023
  9. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    >> Share

  10. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    >> Share

  11. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    >> Share

    September 2023
  12. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    >> Share

  13. CARTWRIGHT EJ, Patel PR
    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    >> Share

  14. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    >> Share

  15. TERRAULT N
    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    >> Share

  16. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    >> Share

  17. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    >> Share

  18. LOU S, Wang J, Chen J, Xie H, et al
    The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon alpha Therapy.
    J Infect Dis. 2023;228:694-703.
    >> Share

  19. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    >> Share

  20. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    >> Share

  21. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    >> Share

  22. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    >> Share

  23. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    >> Share

  24. NJUGUNA HN, Hiebert L, Harris A, Morgan RL, et al
    An Assessment of National Strategic Action Plans for Viral Hepatitis Elimination, 2016-2021.
    J Infect Dis. 2023;228.
    >> Share

  25. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    >> Share

  26. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    >> Share

  27. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    >> Share

  28. YU ML, Ward JW
    Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs.
    J Infect Dis. 2023;228.
    >> Share

  29. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    >> Share

  30. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    >> Share


  31. Correction to: Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues.
    J Infect Dis. 2023 Sep 7:jiad376. doi: 10.1093.
    >> Share

    July 2023
  32. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    >> Share

  33. FIERER DS, Schinkel J
    Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of HCV Among Men Who Have Sex with Men.
    J Infect Dis. 2023 Jul 24:jiad265. doi: 10.1093.
    >> Share

  34. JUNG CY, Jung HY, Kim HW, Ryu GW, et al
    Fibrotic burden in patients with hepatitis B virus-related cirrhosis is independently associated with poorer kidney outcomes.
    J Infect Dis. 2023 Jul 20:jiad273. doi: 10.1093.
    >> Share

    June 2023
  35. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    >> Share

    May 2023
  36. TANG X, Yang L, Zhang P, Wang C, et al
    Occult hepatitis B virus infection is associated with Chinese patients' liver fibrosis.
    J Infect Dis. 2023 May 12:jiad140. doi: 10.1093.
    >> Share

  37. THIO CL, Taddese M, Saad Y, Zambo K, et al
    HBeAg-negative single hepatocyte analysis shows transcriptional silencing and slow decay of infected cells with treatment.
    J Infect Dis. 2023 May 2:jiad124. doi: 10.1093.
    >> Share

    March 2023
  38. WINCHESTER NE, Shrestha NK, Kim P, Tereshchenko LG, et al
    Protection Conferred by Delta and BA.1/BA.2 Infection Against BA.4/BA.5 Infection and Hospitalization: A Retrospective Cohort Study.
    J Infect Dis. 2023;227:800-805.
    >> Share

  39. GAMKRELIDZE A, Shadaker S, Tsereteli M, Alkhazashvili M, et al
    Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021.
    J Infect Dis. 2023 Mar 18:jiad064. doi: 10.1093.
    >> Share

  40. SUEHIRO Y, Tsuge M, Kurihara M, Uchida T, et al
    Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.
    J Infect Dis. 2023;227:686-695.
    >> Share

    February 2023
  41. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
    Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
    J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
    >> Share

    January 2023
  42. THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
    Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
    J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
    >> Share

    December 2022
  43. YU T, Zhang M, Zhang H, Zheng J, et al
    Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues.
    J Infect Dis. 2022 Dec 22:jiac493. doi: 10.1093.
    >> Share

    November 2022
  44. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    >> Share

    October 2022
  45. MILLER-ARCHIE SA, Walters SC, Bocour A, Moore MS, et al
    The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.
    J Infect Dis. 2022;226.
    >> Share

    September 2022
  46. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    >> Share

    August 2022
  47. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study.
    J Infect Dis. 2022;226:420-430.
    >> Share

  48. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    J Infect Dis. 2022;226:431-440.
    >> Share

  49. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication.
    J Infect Dis. 2022;226:407-419.
    >> Share

  50. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    >> Share

    June 2022
  51. PEREZ-GARCIA F, Vazquez-Moron S, Burgueno-Garcia I, Jose Munoz-Gomez M, et al
    Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
    J Infect Dis. 2022 Jun 27. pii: 6618639. doi: 10.1093.
    >> Share

  52. SONNEVELD MJ, Hansen BE, Brouwer WP, Chan HL, et al
    Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.
    J Infect Dis. 2022;225:1967-1973.
    >> Share

    May 2022
  53. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    >> Share

  54. BRAKENHOFF SM, de Knegt RJ, Oliveira J, van der Eijk AA, et al
    Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients.
    J Infect Dis. 2022 May 23. pii: 6590452. doi: 10.1093.
    >> Share

  55. MOHAREB AM, Liu AF, Kim AY, Coffie PA, et al
    Clearance of hepatitis B "e" antigen in untreated chronic HBV infection: a systematic review and meta-analysis.
    J Infect Dis. 2022 May 2. pii: 6576758. doi: 10.1093.
    >> Share

    April 2022
  56. MONTANARI NR, Conceicao-Neto N, Van Den Wyngaert I, Van Oord GW, et al
    Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients.
    J Infect Dis. 2022;225:1471-1476.
    >> Share

    March 2022
  57. RICO MONTANARI N, Ramirez R, Van Buuren N, van den Bosch TPP, et al
    Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen.
    J Infect Dis. 2022;225:1081-1090.
    >> Share

  58. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    >> Share

    February 2022
  59. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    >> Share

    January 2022
  60. SPRADLING PR, Xing J, Zhong Y, Rupp LB, et al
    Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018.
    J Infect Dis. 2022 Jan 17. pii: 6510085. doi: 10.1093.
    >> Share

  61. KHALFI P, Suspene R, Caval V, Thiers V, et al
    APOBEC3C S188I polymorphism enhances context specific editing of Hepatitis B virus genome.
    J Infect Dis. 2022 Jan 12. pii: 6504007. doi: 10.1093.
    >> Share

    December 2021
  62. LIU S, Deng R, Zhou B, Liang X, et al
    Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.
    J Infect Dis. 2021 Dec 21. pii: 6472568. doi: 10.1093.
    >> Share

  63. CHIEN-HUNG C, Peng CY, Kuo YH, Hu TH, et al
    Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.
    J Infect Dis. 2021 Dec 11. pii: 6459556. doi: 10.1093.
    >> Share

  64. COSTAFREDA MI, Sauleda S, Rico A, Piron M, et al
    Detection of non-enveloped hepatitis E virus in plasma of infected blood donors.
    J Infect Dis. 2021 Dec 4. pii: 6449510. doi: 10.1093.
    >> Share

    November 2021
  65. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    >> Share

    September 2021
  66. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    >> Share

  67. AZMAN AS, Paul KK, Bhuiyan TR, Koyuncu A, et al
    Hepatitis E in Bangladesh: Insights from a National Serosurvey.
    J Infect Dis. 2021 Sep 22. pii: 6373659. doi: 10.1093.
    >> Share

  68. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    >> Share

  69. RYDELL GE, Prakash K, Larsson SB, Skoglund C, et al
    Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection.
    J Infect Dis. 2021 Sep 17. pii: 6371942. doi: 10.1093.
    >> Share

    August 2021
  70. CHANG KC, Chang MH, Chen HL, Wu JF, et al
    Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV.
    J Infect Dis. 2021 Aug 7. pii: 6345224. doi: 10.1093.
    >> Share

    July 2021
  71. JOHNSON VALIENTE A, Liem KS, Schwarz KB, Rosenthal P, et al
    The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients.
    J Infect Dis. 2021 Jul 21. pii: 6324833. doi: 10.1093.
    >> Share

  72. SPRADLING PR, Xing J, Harris AM, Ly KN, et al
    Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018.
    J Infect Dis. 2021 Jul 12. pii: 6319558. doi: 10.1093.
    >> Share

  73. GU S, Wang W, Ye G, Chen C, et al
    Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells.
    J Infect Dis. 2021 Jul 2. pii: 6313212. doi: 10.1093.
    >> Share

    June 2021
  74. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    >> Share

    May 2021
  75. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    >> Share

    April 2021
  76. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    >> Share

  77. LY KN, Xing J, Spradling PR
    Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018.
    J Infect Dis. 2021 Apr 27. pii: 6254685. doi: 10.1093.
    >> Share

  78. YUAN W, Huang D, Wu D, Chen Y, et al
    Peg IFN-a Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-gamma in Chronic Hepatitis B.
    J Infect Dis. 2021 Apr 19. pii: 6236316. doi: 10.1093.
    >> Share

  79. LIU Z, Huang CJ, Huang YH, Pan MH, et al
    HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.
    J Infect Dis. 2021 Apr 14. pii: 6225842. doi: 10.1093.
    >> Share

    March 2021
  80. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    >> Share

    February 2021
  81. WU W, Wu D, Yan W, Wang Y, et al
    Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    J Infect Dis. 2021;223:686-698.
    >> Share

    October 2020
  82. YOSHIKAWA S, Yoshio S, Yoshida Y, Tsutsui Y, et al
    Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.
    J Infect Dis. 2020 Oct 19. pii: 5929874. doi: 10.1093.
    >> Share

    August 2020
  83. WU JF, Chang KC, Ni YH, Hsu HY, et al
    Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion.
    J Infect Dis. 2020 Aug 29. pii: 5899201. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016